Springworks Therapeutics logo

Springworks Therapeutics share price today

(NASDAQ: SWTX)

Springworks Therapeutics share price is $35 & ₹3,027.15 as on 23 Jan 2025, 20.32 hrs IST

$35

-1.35

(-3.71%)

Market is closed - opens 8 PM, 23 Jan 2025

View live Springworks Therapeutics share price in Dollar and Rupees. Guide to invest in Springworks Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Springworks Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Springworks Therapeutics share price movements

  • Today's Low: $34.40
    Today's High: $36.75

    Day's Volatility :6.41%

  • 52 Weeks Low: $28.21
    52 Weeks High: $53.92

    52 Weeks Volatility :47.68%

Springworks Therapeutics Returns

PeriodSpringworks Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
20.23%
-5.5%
0.0%
6 Months
-5.07%
-4.3%
0.0%
1 Year
-14.99%
1.6%
0.0%
3 Years
-37.13%
9.8%
-11.0%

Springworks Therapeutics Key Statistics

in dollars & INR

Previous Close
$35.0
Open
$35.76
Today's High
$35.34
Today's Low
$34.42
Market Capitalization
$2.6B
Today's Volume
$1.7M
52 Week High
$53.92
52 Week Low
$28.21
Revenue TTM
$135.5M
EBITDA
$-292.3M
Earnings Per Share (EPS)
$-3.89
Profit Margin
-203.09%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-59.33%

How to invest in Springworks Therapeutics Stock (SWTX) from India?

It is very easy for Indian residents to invest directly in Springworks Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Springworks Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Springworks Therapeutics or SWTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Springworks Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Springworks Therapeutics shares which would translate to 0.025 fractional shares of Springworks Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Springworks Therapeutics, in just a few clicks!

Returns in Springworks Therapeutics for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Springworks Therapeutics investment value today

Current value as on today

₹89,068

Returns

₹10,932

(-10.93%)

Returns from Springworks Therapeutics Stock

₹14,987 (-14.99%)

Dollar Returns

₹4,054 (+4.05%)

Indian investors sentiment towards Springworks Therapeutics

167%

Period: Oct 24, 2024 to Jan 22, 2025. Change in 30 Days versus previous period

Search volume for Springworks Therapeutics on INDmoney from India has grown in the last 30 days as on Jan 23, 2025. 167% more investors are searching Springworks Therapeutics in the last 30 days versus the previous period.

Global Institutional Holdings in Springworks Therapeutics

  • FMR Inc

    14.98%

  • Vanguard Group Inc

    9.02%

  • BlackRock Inc

    7.99%

  • Deep Track Capital, LP

    5.17%

  • T. Rowe Price Associates, Inc.

    4.73%

  • Boxer Capital LLC

    4.60%

Analyst Recommendation on Springworks Therapeutics

Buy

    93%Buy

    6%Hold

    0%Sell

Based on 15 Wall street analysts offering stock ratings for Springworks Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
14
14
12
Hold
1
1
1
Sell
0
0
0

Analyst Forecast on Springworks Therapeutics

What analysts predicted

Upside of 92.86%

Target:

$67.50

Current:

$35.00

Insights on Springworks Therapeutics

  • Price Movement

    In the last 1 month, SWTX stock has moved down by -6.3%
  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 59.73M → 49.30M (in $), with an average decrease of 17.5% per quarter
  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -39.91M → -53.53M (in $), with an average decrease of 34.1% per quarter
  • SWTX vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 40.5% return, outperforming this stock by 56.7%
  • SWTX vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 95.4% return, outperforming this stock by 130.9%
  • Price to Sales

    ForSWTX every $1 of sales, investors are willing to pay $18.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.1 for every $1 of sales.

Springworks Therapeutics Technicals Summary

Sell

Neutral

Buy

Springworks Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Springworks Therapeutics Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Springworks Therapeutics Inc logo
-4.92%
-5.07%
-14.99%
-37.13%
-8.59%
Biontech Se logo
0.91%
36.01%
16.45%
-23.72%
246.9%
Regeneron Pharmaceuticals, Inc. logo
-4.82%
-36.1%
-28.29%
9.42%
100.35%
Vertex Pharmaceuticals Incorporated logo
4.86%
-13.05%
0.1%
86.35%
88.24%
Alnylam Pharmaceuticals, Inc. logo
9.57%
12.05%
43.92%
95.22%
127.75%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Springworks Therapeutics Inc logo
NA
NA
NA
-3.15
-0.59
-0.34
NA
7.17
Biontech Se logo
160.8
NA
0.04
-3.33
-0.02
-0.01
NA
79.73
Regeneron Pharmaceuticals, Inc. logo
17.02
17.02
1.05
44.99
0.17
0.07
NA
272.04
Vertex Pharmaceuticals Incorporated logo
32.84
NA
1.1
0.48
-0.03
0.12
NA
60.65
Alnylam Pharmaceuticals, Inc. logo
NA
NA
-0.49
-0.18
-15.01
-0.03
NA
0.25
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Springworks Therapeutics Inc logo
Buy
$2.6B
-8.59%
NA
-203.09%
Biontech Se logo
Buy
$28.1B
246.9%
160.8
-15.36%
Regeneron Pharmaceuticals, Inc. logo
Buy
$75.6B
100.35%
17.02
33.61%
Vertex Pharmaceuticals Incorporated logo
Buy
$110.2B
88.24%
32.84
-4.51%
Alnylam Pharmaceuticals, Inc. logo
Buy
$34.2B
127.75%
NA
-15.86%

Springworks Therapeutics Dividend announcements

  • Springworks Therapeutics Earnings

    Springworks Therapeutics’s price-to-earnings ratio stands at None

    Read More

About Springworks Therapeutics

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer. The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas. In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.
Organization
Springworks Therapeutics
Employees
305
CEO
Mr. Saqib Islam J.D.
Industry
Health Technology

Management People of Springworks Therapeutics

NameTitle
Mr. Saqib Islam J.D.
CEO & Director
Mr. Francis I. Perier Jr., M.B.A.
Chief Financial Officer
Dr. Badreddin Edris Ph.D.
Chief Operating Officer
Dr. James Cassidy M.D., Ph.D.
Chief Medical Officer
Mr. Michael P. Nofi
Chief Accounting Officer
Mr. Tai-An Lin Ph.D.
Chief Scientific Officer
Ms. Kim Diamond
Vice President of Communications & Investor Relations
Mr. Herschel S. Weinstein J.D.
General Counsel & Secretary
Mr. Daniel J. Pichl
Chief People Officer
Mr. Bhavesh Ashar M.B.A.
Chief Commercial Officer

Important FAQs about investing in Springworks Therapeutics (SWTX) from India :

What is Springworks Therapeutics share price today?

Springworks Therapeutics share price today stands at $35.00, Open: $35.76 ; Previous Close: $36.35 ; High: $36.75 ; Low: $34.40 ; 52 Week High: $53.92 ; 52 Week Low: $28.21. The stock opens at $35.76, after a previous close of $36.35. The stock reached a daily high of $36.75 and a low of $34.40, with a 52-week high of $53.92 and a 52-week low of $28.21.

Can Indians buy Springworks Therapeutics shares?

Yes, Indians can invest in the Springworks Therapeutics (SWTX) from India.

With INDmoney, you can buy Springworks Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Springworks Therapeutics at zero transaction cost.

How can I buy Springworks Therapeutics shares from India?

It is very easy to buy Springworks Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Springworks Therapeutics be purchased?

Yes, you can buy fractional shares of Springworks Therapeutics with INDmoney app.

What are the documents required to start investing in Springworks Therapeutics stocks?

To start investing in Springworks Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Springworks Therapeutics

Today’s highest price of Springworks Therapeutics (SWTX) is $36.75.

Today’s lowest price of Springworks Therapeutics (SWTX) is $34.40.

What is today's market capitalisation of Springworks Therapeutics

Today's market capitalisation of Springworks Therapeutics SWTX is 2.6B

What is the 52 Week High and Low Range of Springworks Therapeutics

  • 52 Week High

    $53.92

  • 52 Week Low

    $28.21

What are the historical returns of Springworks Therapeutics?

  • 1 Month Returns

    -4.92%

  • 3 Months Returns

    -5.07%

  • 1 Year Returns

    -14.99%

  • 5 Years Returns

    -8.59%

Who is the Chief Executive Officer (CEO) of Springworks Therapeutics

Mr. Saqib Islam J.D. is the current Chief Executive Officer (CEO) of Springworks Therapeutics.